These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38834171)

  • 21. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
    Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
    Demir N; Sevincli S; Kayhan B; Sonmez M
    Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Factors for Long-Term Outcomes of Cataract Surgery in Patients Receiving Active Treatment for Neovascular Age-Related Macular Degeneration.
    Choi EY; Kim TY; Lee CS
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and Clinical Practice of Exudative Age-related Macular Degeneration: A Nationwide Population-Based Cohort Study.
    Kido A; Miyake M; Tamura H; Hiragi S; Kimura T; Yoshida S; Takeuchi M; Ohtera S; Takahashi A; Ooto S; Kawakami K; Kuroda T; Tsujikawa A
    Ophthalmol Sci; 2022 Jun; 2(2):100125. PubMed ID: 36249688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
    Eng VA; Rayess N; Nguyen HV; Leng T
    PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-year mortality and long-term visual acuity outcomes in patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections.
    Young SL; Anderson MJ; Borooah S; Armbrecht AM; Cackett PD
    Age Ageing; 2022 Jan; 51(1):. PubMed ID: 34977924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 28. The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study.
    Talks SJ; Daien V; Mitchell P; Aslam T; Barratt J; Biberger A; Lamoureux EL; Hirst C; Sylvanowicz M; Finger RP
    Ophthalmol Ther; 2023 Feb; 12(1):561-575. PubMed ID: 36525220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.
    Hanhart J; Comaneshter DS; Freier-Dror Y; Vinker S
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):651-663. PubMed ID: 29429131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Therapies of Neovascular AMD-Beyond Anti-VEGFs.
    Yerramothu P
    Vision (Basel); 2018 Jul; 2(3):. PubMed ID: 31735894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Obeid A; Gao X; Ali FS; Aderman CM; Shahlaee A; Adam MK; Kasi SK; Hyman L; Ho AC; Hsu J
    JAMA Ophthalmol; 2018 Nov; 136(11):1251-1259. PubMed ID: 30352121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1.
    Gale RP; Airody A; Sivaprasad S; Hanson RLW; Allgar V; McKibbin M; Morland AB; Peto T; Porteous M; Chakravarthy U;
    Ophthalmol Retina; 2024 Jun; 8(6):545-552. PubMed ID: 38171416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study.
    Lee WA; Shao SC; Liao TC; Lin SJ; Lai CC; Lai EC
    BioDrugs; 2022 Mar; 36(2):205-216. PubMed ID: 35230656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration.
    Kabanarou SA; Xirou T; Mangouritsas G; Garnavou-Xirou C; Boutouri E; Gkizis I; Chatziralli I
    Clin Interv Aging; 2017; 12():911-915. PubMed ID: 28603410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
    Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
    Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
    Ciulla TA; Hussain RM; Pollack JS; Williams DF
    Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
    Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
    J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40.
    Christakis PG; Agrón E; Klein ML; Clemons TE; Campbell JP; Ferris FL; Chew EY; Keenan TD;
    Ophthalmology; 2020 Jun; 127(6):784-792. PubMed ID: 31899035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland.
    Korva-Gurung I; Kubin AM; Ohtonen P; Hautala N
    Ann Med; 2023 Dec; 55(1):2222545. PubMed ID: 37306515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetic Association between Allelic Variants of the Autophagy-Related Genes and Anti-Vascular Endothelial Growth Factor Treatment Response in Neovascular Age-Related Macular Degeneration.
    Kozhevnikova OS; Fursova AZ; Derbeneva AS; Nikulich IF; Devyatkin VA; Kolosova NG
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.